Head-to-head evidence
Albuterol sulfate (Armstrong) vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Albuterol sulfate (Armstrong)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634517 · Phase 3 · terminated
This is a randomized, quadruple-blind, active-controlled study directly measuring lung function, but the sample size is small for a pediatric population and no results have been posted yet, so the outcome is unknown.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
Vilanterol
Marketed by GlaxoSmithKline
NCT01706198 · Phase 3 · completed
The study randomized 4,233 participants to FF/VI or active usual care, but neither participants nor investigators were blinded. Its primary patient-reported asthma-control endpoint was a surrogate/soft measure and was met in favor of FF/VI (71% vs 56%; p<0.001), supporting moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuterol sulfate (Armstrong)'s landscape · Vilanterol's landscape